Institute of Public Health, Charité- Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
Institute of Biometry and Clinical Epidemiology, Charité- Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
BMC Geriatr. 2024 Apr 12;24(1):335. doi: 10.1186/s12877-024-04887-5.
Frailty and polypharmacy are common conditions in older adults, especially in those with chronic kidney disease (CKD). Therefore, we analyzed the association of polypharmacy and incident frailty and the effect modification by CKD in very old adults.
In non-frail individuals within the Berlin Initiative (cohort) Study, polypharmacy (≥ 5 medications) was assessed according to multiple definitions based on the number of regular and on demand prescription and over the counter drugs, as well as vitamins and supplements. CKD was defined as an estimated glomerular filtration rate < 60 mL/min/1.73m and/or an albumin-creatinine ratio ≥ 30 mg/g. Incident frailty was assessed at follow-up using Fried criteria. Logistic regression was applied to assess (1) the association of different polypharmacy definitions with incident frailty and (2) effect modification by CKD.
In this cohort study, out of 757 non-frail participants (mean age 82.9 years, 52% female, 74% CKD), 298 (39%) participants reported polypharmacy. Over the observation period of 2.1 years, 105 became frail. Individuals with polypharmacy had 1.96 adjusted odds (95% confidence interval (CI): 1.20-3.19) of becoming frail compared to participants without polypharmacy. The effect of polypharmacy on incident frailty was modified by CKD on the additive scale (relative excess risk due to interaction: 1.56; 95% CI 0.01-3.12).
This study demonstrates an association of polypharmacy and incident frailty and suggests strong evidence for an effect modification of CKD on polypharmacy and incident frailty. Revision of prescriptions could be a target strategy to prevent frailty occurrence, especially in older adults with CKD.
衰弱和多种药物治疗在老年人中很常见,尤其是在患有慢性肾脏病(CKD)的老年人中。因此,我们分析了多种药物治疗与衰弱发生的相关性,以及 CKD 对衰弱发生的修饰作用。
在柏林倡议(队列)研究中的非衰弱个体中,根据基于定期和按需处方以及非处方药和维生素及补充剂数量的多种定义,评估多种药物治疗(≥5 种药物)。CKD 的定义为估计肾小球滤过率<60 mL/min/1.73m2和/或白蛋白-肌酐比值≥30 mg/g。在随访时使用 Fried 标准评估衰弱的发生。应用逻辑回归评估(1)不同多种药物治疗定义与衰弱发生的相关性,(2)CKD 的修饰作用。
在这项队列研究中,在 757 名非衰弱参与者(平均年龄 82.9 岁,52%为女性,74%患有 CKD)中,有 298 名(39%)参与者报告存在多种药物治疗。在 2.1 年的观察期间,有 105 名参与者变得衰弱。与无多种药物治疗的参与者相比,存在多种药物治疗的个体发生衰弱的调整比值比为 1.96(95%置信区间(CI):1.20-3.19)。多种药物治疗对衰弱发生的影响在加性尺度上受 CKD 修饰(交互的相对超额风险:1.56;95%CI 0.01-3.12)。
这项研究表明多种药物治疗与衰弱发生相关,并提示 CKD 对多种药物治疗和衰弱发生具有很强的修饰作用。修订处方可能是预防衰弱发生的目标策略,尤其是在患有 CKD 的老年患者中。